Apollo Hospital's arm to introduce Clinical Genomic tests

16 May 2014 Evaluate

Apollo Hospital's subsidiary, Sapien Biosciences will introduce several genomic tests, over the next few months, as part of its personalized medicine initiative. Genomic testing involves analyses of the patient genomes and translating insights gained from these analyses to develop better healthcare interventions by the way of better prognostic tools for improved disease screening and prevention strategies, better diagnostic tests for optimization of clinical care and better theranostic tests for personalization of treatment.

The first of these tests is to be launched shortly; there shall be a clinical genomics panel for oncology that is designed to identify the mutations that drive cancer initiation and progression. Insights obtained from this test will enable prediction of the patient's response to their medication allowing the physician to tailor the treatment to the patient's genomic profile.

Apollo Hospitals is the leading private sector healthcare provider in Asia and owns and manages a network of speciality hospitals and clinics, a chain of Pharmacy retail outlets across the country, and provides Consultancy Services for commissioning and managing the Speciality Hospitals.

Apollo Hospital Ent. Share Price

7063.75 21.15 (0.30%)
01-Jan-2026 10:25 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7063.75
Max Healthcare Inst 1041.85
Narayana Hrudayalay 1877.00
Aster DM Healthcare 606.65
Global Health 1190.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×